Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27838365 | 0.89 | KDM4E (0.40) | L3MBTL1POLBKDM4ERECQLALDH1A1 | |
| SCHEMBL6525329 | 0.86 | ALDH1A1 (0.39) | L3MBTL1KDM4ERECQLALDH1A1TSHR | |
| SCHEMBL24308002 | 0.79 | KDM4E (0.36) | L3MBTL1POLBKDM4ERECQLALDH1A1 | |
| SCHEMBL7290876 | 0.78 | — | — | |
| SCHEMBL12801250 | 0.78 | — | — | |
| SCHEMBL9407518 | 0.77 | L3MBTL1 (0.41) | L3MBTL1POLBKDM4ERECQLALDH1A1 | |
| SCHEMBL9546919 | 0.77 | — | — | |
| SCHEMBL6525778 | 0.77 | ANPEP (0.39) | — | |
| SCHEMBL17065937 | 0.75 | — | — | |
| SCHEMBL21244317 | 0.75 | CA12 (0.43) | KDM4ERECQLALDH1A1TSHRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296931-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4558483-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546576-A | Novel isoquinolinones pyrrolo-pyridones and thieno pyridone sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024017856-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-2318378-B1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2013-10-23 | — | — | EP | disclosed |
| EP-2318378-B1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2013-10-23 | — | — | EP | disclosed |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-08-22 | — | — | US | disclosed |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-08-22 | — | — | US | disclosed |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-08-22 | — | — | US | disclosed |
| US-8426430-B2 | Quinazoline derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-04-23 | — | — | US | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | L3MBTL1 1220/4885POLB 619/4885KDM4E 379/4885 |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | L3MBTL1 1021/4885POLB 2801/4885KDM4E 904/4885 |
| US-20250296931-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | SULT1E1, XDH, PRXL2A | L3MBTL1 4824/4885POLB 1497/4885KDM4E 2689/4885 |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | L3MBTL1 1021/4885POLB 2801/4885KDM4E 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.